Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring

Cancer and Metastasis Reviews

Volumn 34, Issue 1, 2015, Pages 145-155

  McGuire, Andrew ^a   Brown, James A L ^a   Kerin, Michael J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Biomarker; Breast cancer; Metastatic; Metastatic rates; Metastatic sites; miRNA; Subtype

Indexed keywords

MICRORNA; TUMOR MARKER;

BLOOD; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METASTASIS; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM METASTASIS; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84925441762     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-015-9551-7     Document Type: Article

References (125)

1. Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 63, 11.
2. Jemal, A., et al. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61, 69.
3. Hunter, K. W., Crawford, N. P., & Alsarraj, J. (2008). Mechanisms of metastasis. Breast Cancer Research, 10(Suppl 1), S2.
4. Scully, O. J., Bay, B. H., Yip, G., & Yu, Y. (2012). Breast cancer metastasis. Cancer Genomics Proteomics, 9, 311.
5. Weigelt, B., Peterse, J. L., & van ’t Veer, L. J. (2005). Breast cancer metastasis: markers and models. Nature Reviews Cancer, 5, 591.
6. Heneghan, H. M., et al. (2010). Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Annals of Surgery, 251, 499.
7. Roth, C., et al. (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Research, 12, R90.
8. Bartels, C. L., & Tsongalis, G. J. (2009). MicroRNAs: novel biomarkers for human cancer. Clinical Chemistry, 55, 623.
9. Rask, L., et al. (2014). Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. Cellular Oncology (Dordr), 37, 215.
10. Smeets, A., et al. (2011). Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. Breast Cancer Research and Treatment, 129, 767.
11. Shen, S., et al. (2014). A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PloS One, 9, e100664.
12. Yu, F., et al. (2007). let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 131, 1109.
13. Ye, Z. B., et al. (2015). miR-429 inhibits migration and invasion of breast cancer cells in vitro. International Journal of Oncology, 46, 531.
14. S. M. Yahya, G. H. Elsayed (2014) A summary for molecular regulations of miRNAs in breast cancer. Clinical Biochemistry.
15. Dykxhoorn, D. M. (2010). MicroRNAs and metastasis: little RNAs go a long way. Cancer Research, 70, 6401.
16. Esquela-Kerscher, A., & Slack, F. J. (2006). Oncomirs—microRNAs with a role in cancer. Nature Reviews Cancer, 6, 259.
17. Calin, G. A., et al. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 99, 15524.
18. Lawrie, C. H., et al. (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. British Journal of Haematology, 141, 672.
19. Lujambio, A., & Lowe, S. W. (2012). The microcosmos of cancer. Nature, 482, 347.
20. Croce, C. M., & Calin, G. A. (2005). miRNAs, cancer, and stem cell division. Cell, 122, 6.
21. Christodoulatos, G. S., & Dalamaga, M. (2014). Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis? World Journal of Clinical Oncology, 5, 71.
22. Kent, O. A., & Mendell, J. T. (2006). A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene, 25, 6188.
23. Calin, G. A., et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America, 101, 2999.
24. McDermott, A. M., et al. (2014). Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. PloS One, 9, e87032.
25. Lowery, A. J., et al. (2009). MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Research, 11, R27.
26. Anfossi, S., et al. (2014). High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PloS One, 9, e83113.
27. Toyama, T., et al. (2012). High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Japanese Journal of Clinical Oncology, 42, 256.
28. Munker, R., & Calin, G. A. (2011). MicroRNA profiling in cancer. Clinical Science (London), 121, 141.
29. He, L., & Hannon, G. J. (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nature Reviews Genetics, 5, 522.
30. Arroyo, J. D., et al. (2011). Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proceedings of the National Academy of Sciences of the United States of America, 108, 5003.
31. Vella, L. J. (2014). The emerging role of exosomes in epithelial-mesenchymal-transition in cancer. Frontiers in Oncology, 4, 361.
32. Lu, J., et al. (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834.
33. Perou, C. M., et al. (2000). Molecular portraits of human breast tumours. Nature, 406, 747.
34. Goldhirsch, A., et al. (2011). Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology, 22, 1736.
35. Eroles, P., Bosch, A., Perez-Fidalgo, J. A., & Lluch, A. (2012). Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treatment Reviews, 38, 698.
36. Eiermann, W., et al. (2013). The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Annals of Oncology, 24, 618.
37. Dobbe, E., Gurney, K., Kiekow, S., Lafferty, J. S., & Kolesar, J. M. (2008). Gene-expression assays: new tools to individualize treatment of early-stage breast cancer. American Journal of Health-System Pharmacy, 65, 23.
38. Baffa, R., et al. (2009). MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. Journal of Pathology, 219, 214.
39. Shi, M., Liu, D., Duan, H., Shen, B., & Guo, N. (2010). Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer and Metastasis Reviews, 29, 785.
40. Guttery, D. S., et al. (2013). Hide and seek: tell-tale signs of breast cancer lurking in the blood. Cancer and Metastasis Reviews, 32, 289.
41. Zhang, J., & Ma, L. (2012). MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer and Metastasis Reviews, 31, 653.
42. Mitchell, P. S., et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America, 105, 10513.
43. Wang, L., & Wang, J. (2012). MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. Oncogene, 31, 2499.
44. Jang, K., et al. (2014). Loss of microRNA-200a expression correlates with tumor progression in breast cancer. Translational Research: The Journal of Laboratory and Clinical Medicine, 163, 242.
45. Markou, A., Yousef, G. M., Stathopoulos, E., Georgoulias, V., & Lianidou, E. (2014). Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up. Clinical Chemistry, 60, 197.
46. Cascione, L., et al. (2013). Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PloS One, 8, e55910.
47. Hafez, M. M., et al. (2012). MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Asian Pacific Journal of Cancer Prevention: APJCP, 13, 591.
48. Tavazoie, S. F., et al. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451, 147.
49. Valastyan, S., et al. (2009). A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell, 137, 1032.
50. Li, F., Tiede, B., Massague, J., & Kang, Y. (2007). Beyond tumorigenesis: cancer stem cells in metastasis. Cell Research, 17, 3.
51. Singh, S. K., et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Research, 63, 5821.
52. Cuiffo, B. G., et al. (2014). MSC-Regulated MicroRNAs Converge on the Transcription Factor FOXP2 and Promote Breast Cancer Metastasis. Cell Stem Cell, 15, 762.
53. Gupta, G. P., & Massague, J. (2006). Cancer metastasis: building a framework. Cell, 127, 679.
54. Muller, A., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410, 50.
55. Ernst, M. F., et al. (2007). Trends in the prognosis of patients with primary metastatic breast cancer diagnosed between 1975 and 2002. Breast, 16, 344.
56. Ren, Z., Li, Y., Hameed, O., Siegal, G. P., & Wei, S. (2014). Prognostic factors in patients with metastatic breast cancer at the time of diagnosis. Pathology Research and Practice, 210, 301.
57. Morris, P. G., et al. (2010). Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. Journal of Clinical Oncology, 28, 3154.
58. Barnholtz-Sloan, J. S., et al. (2004). Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. Journal of Clinical Oncology, 22, 2865.
59. Sihto, H., et al. (2011). Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Research, 13, R87.
60. Berman, A. T., Thukral, A. D., Hwang, W. T., Solin, L. J., & Vapiwala, N. (2013). Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clinical Breast Cancer, 13, 88.
61. Kennecke, H., et al. (2010). Metastatic behavior of breast cancer subtypes. Journal of Clinical Oncology, 28, 3271.
62. J. M. Matro et al. (2014) Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome. Clinical Breast Cancer.
63. Smid, M., et al. (2008). Subtypes of breast cancer show preferential site of relapse. Cancer Research, 68, 3108.
64. C. Aversa et al. (2014) Metastatic breast cancer subtypes and central nervous system metastases. Breast.
65. Lowery, A. J., Kell, M. R., Glynn, R. W., Kerin, M. J., & Sweeney, K. J. (2012). Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Research and Treatment, 133, 831.
66. Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer, 109, 1721.
67. Carey, L. A., et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492.
68. Ihemelandu, C. U., et al. (2007). Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. Journal of Surgical Research, 143, 109.
69. Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009). Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clinical Medicine & Research, 7, 4.
70. Piccart-Gebhart, M. J., et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine, 353, 1659.
71. Gianni, L., et al. (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. The Lancet Oncology, 12, 236.
72. Bosch, A., Eroles, P., Zaragoza, R., Vina, J. R., & Lluch, A. (2010). Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treatment Reviews, 36, 206.
73. Parker, J. S., et al. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology, 27, 1160.
74. Blenkiron, C., et al. (2007). MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biology, 8, R214.
75. Enerly, E., et al. (2011). miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PloS One, 6, e16915.
76. Janssen, E. A., et al. (2010). Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Modern Pathology, 23, 1567.
77. Li, Y., et al. (2013). microRNA-210 as a prognostic factor in patients with breast cancer: meta-analysis. Cancer Biomarkers, 13, 471.
78. Volinia, S., & Croce, C. M. (2013). Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 110, 7413.
79. Avery-Kiejda, K. A., Braye, S. G., Mathe, A., Forbes, J. F., & Scott, R. J. (2014). Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC Cancer, 14, 51.
80. Farazi, T. A., et al. (2011). MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Research, 71, 4443.
81. Jacobson, J. A., et al. (1995). Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. New England Journal of Medicine, 332, 907.
82. Fyles, A. W., et al. (2004). Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. New England Journal of Medicine, 351, 963.
83. G. Early Breast Cancer Trialists’ Collaborative. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687.
84. Rossi, M., et al. (2013). From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. Current Drug Targets, 14, 1144.
85. Pereira, D. M., Rodrigues, P. M., Borralho, P. M., & Rodrigues, C. M. (2013). Delivering the promise of miRNA cancer therapeutics. Drug Discovery Today, 18, 282.
86. Uchino, K., Ochiya, T., & Takeshita, F. (2013). RNAi therapeutics and applications of microRNAs in cancer treatment. Japanese Journal of Clinical Oncology, 43, 596.
87. Conde, J., & Artzi, N. (2015). Are RNAi and miRNA therapeutics truly dead? Trends in Biotechnology(Jan 13).
88. De Laurentiis, M., et al. (2008). Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. Journal of Clinical Oncology, 26, 44.
89. Slamon, D. J., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344, 783.
90. Zambetti, M., et al. (2012). Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Research and Treatment, 132, 843.
91. Chen, J., Tian, W., Cai, H., He, H., & Deng, Y. (2012). Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Medical Oncology, 29, 2527.
92. P. Freres et al. (2014) Neoadjuvant chemotherapy in breast cancer patients induces miR-34a and miR-122 expression. Journal of Cellular Physiology.
93. Hoppe, R., et al. (2013). Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. European Journal of Cancer, 49, 3598.
94. Jung, E. J., et al. (2012). Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 118, 2603.
95. Sun, Y., et al. (2012). Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PloS One, 7, e47003.
96. Wang, H., et al. (2012). Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PloS One, 7, e34210.
97. Li, Q., et al. (2014). Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PloS One, 9, e104870.
98. Gasparini, P., et al. (2014). microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget, 5, 1174.
99. Hubbard, R. A., et al. (2011). Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Annals of Internal Medicine, 155, 481.
100. Wiatrek, R., & Kruper, L. (2011). Sentinel lymph node biopsy indications and controversies in breast cancer. Maturitas, 69, 7.
101. Cheng, G., Kurita, S., Torigian, D. A., & Alavi, A. (2011). Current status of sentinel lymph-node biopsy in patients with breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 38, 562.
102. Zhou, W., et al. (2014). Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell, 25, 501.
103. Asaga, S., et al. (2011). Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clinical Chemistry, 57, 84.
104. Madhavan, D., et al. (2012). Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clinical Cancer Research, 18, 5972.
105. van Schooneveld, E., et al. (2012). Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Research, 14, R34.
106. Schwarzenbach, H., Milde-Langosch, K., Steinbach, B., Muller, V., & Pantel, K. (2012). Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Research and Treatment, 134, 933.
107. Eichelser, C., Flesch-Janys, D., Chang-Claude, J., Pantel, K., & Schwarzenbach, H. (2013). Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clinical Chemistry, 59, 1489.
108. Chen, W., Cai, F., Zhang, B., Barekati, Z., & Zhong, X. Y. (2013). The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biology, 34, 455.
109. Ahmad, A., et al. (2014). Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis. American Journal of Translational Research, 6, 384.
110. Zhao, F. L., et al. (2012). Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. Journal of International Medical Research, 40, 859.
111. Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449, 682.
112. Song, S. J., et al. (2013). MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell, 154, 311.
113. Huang, Q., et al. (2008). The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nature Cell Biology, 10, 202.
114. Yan, L. X., et al. (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14, 2348.
115. Shivapurkar, N., et al. (2014). Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. PloS One, 9, e84686.
116. Kjersem, J. B., et al. (2014). Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Molecular Oncology, 8, 59.
117. Wang, L. G., & Gu, J. (2012). Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiology, 36, e61.
118. Toiyama, Y., et al. (2014). Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Annals of Surgery, 259, 735.
119. Gonzales, J. C., et al. (2011). Comparison of circulating microRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clinical Genitourinary Cancer, 9, 39.
120. Zhang, H. L., et al. (2013). An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian Journal of Andrology, 15, 231.
121. Nguyen, H. C., et al. (2013). Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate, 73, 346.
122. Zhao, S., Yao, D., Chen, J., & Ding, N. (2013). Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer. Genetic Testing and Molecular Biomarkers, 17, 631.
123. Kim, S. Y., et al. (2013). Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. Journal of Molecular Diagnostics, 15, 661.
124. Chen, J., et al. (2013). Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. International Journal of Molecular Medicine, 32, 557.
125. Dai, X., Chen, A., & Bai, Z. (2014). Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. Science Reports, 4, 6566.